CA2197869A1 - Therapeutic agent for cartilaginous diseases - Google Patents

Therapeutic agent for cartilaginous diseases

Info

Publication number
CA2197869A1
CA2197869A1 CA002197869A CA2197869A CA2197869A1 CA 2197869 A1 CA2197869 A1 CA 2197869A1 CA 002197869 A CA002197869 A CA 002197869A CA 2197869 A CA2197869 A CA 2197869A CA 2197869 A1 CA2197869 A1 CA 2197869A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
hgf
accelerator
cartilaginous
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002197869A
Other languages
French (fr)
Other versions
CA2197869C (en
Inventor
Masahiro Iwamoto
Sumihare Noji
Toshikazu Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP21816494A external-priority patent/JP3737532B2/en
Application filed by Individual filed Critical Individual
Publication of CA2197869A1 publication Critical patent/CA2197869A1/en
Application granted granted Critical
Publication of CA2197869C publication Critical patent/CA2197869C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a therapeutic agent for cartilaginous diseases, an accelerator for chondrocyte proliferation and an accelerator for proteoglycan production comprising HGF (hepatocyte growth factor) as an active component, and a treatment method for cartilaginous diseases of human or mammals comprising administering an effective amount of HGF. The active component HGF has an effect to promote the proliferation of chondrocytes and to promote the production of proteoglycan. Therefore, the therapeutic agent and accelerator of the present invention are useful for the prevention and treatment of various disorders caused by cartilaginous diseases.
CA002197869A 1994-08-19 1995-01-30 Therapeutic agent for cartilaginous diseases Expired - Fee Related CA2197869C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP21816494A JP3737532B2 (en) 1994-08-19 1994-08-19 Cartilage disorder treatment
JP218164/1994 1994-08-19
PCT/JP1995/000121 WO1996005855A1 (en) 1994-08-19 1995-01-30 Cartilage disease remedy

Publications (2)

Publication Number Publication Date
CA2197869A1 true CA2197869A1 (en) 1996-02-29
CA2197869C CA2197869C (en) 2007-01-02

Family

ID=37603346

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002197869A Expired - Fee Related CA2197869C (en) 1994-08-19 1995-01-30 Therapeutic agent for cartilaginous diseases

Country Status (1)

Country Link
CA (1) CA2197869C (en)

Also Published As

Publication number Publication date
CA2197869C (en) 2007-01-02

Similar Documents

Publication Publication Date Title
MX9603479A (en) 4-amino derivatives of mycophenolic acid with immunosuppressant activity.
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
DE69625906D1 (en) DINUCLEOTIDES FOR USE IN THE TREATMENT OF LUNG DISEASES
TW262461B (en)
BG106095A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
UA41906C2 (en) Method for treating neurological disorders due to trauma
UA56989C2 (en) PHYSIOLOGICALLY ACTIVE PEG-CONJUGATE OF a-INTERFERON, A METHOD FOR PREPARING THE SAME, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR TREATMENT OR PROPHYLAXIS OF IMMUNOMODULAR DISEASES
CA2294247A1 (en) Antioxidant enhancement of therapy for hyperproliferative conditions
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
ES2150294T3 (en) COMPOSITION OF L-DOPA ESTERS.
CA2289717A1 (en) Novel therapy for constipation
SI0801564T1 (en) Use of nebivolol as an anti-atherogenic
HUT78058A (en) Analogs of keratinocyte growth factor
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
AU569920B2 (en) Administration of gangliosides by inhalation
MX9805141A (en) USE OF INHIBITORS OF THE CELLULAR Na+/H+ EXCHANGER (NHE) FOR THE PREPARATION OF A DRUG FOR RESPIRATORY STIMULATION.
WO1996030042A3 (en) Methods of treating inflammation and compositions therefor
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
DE69501359D1 (en) Use of phosphate diesters for the treatment of diseases of the retina
CA2197869A1 (en) Therapeutic agent for cartilaginous diseases
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
AU4530796A (en) Treating disorders characterised by excessive cell proliferation with sclareolide
EP0904094A4 (en) Treatment of bone disorders with adrenomedullin

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140130